Taxonomic and mechanistic insights into gut microbiota bioaccumulation of entacapone using bioorthogonal drug labelling

Abstract

Aim: The gut microbiota plays a key role in shaping individual responses to drugs, but current tools have limited potential to probe drug-microbe interactions within the complex, individualised gut environment. This study employed bioorthogonal labelling to track and identify gut microbial taxa and molecular mechanisms involved in the bioaccumulation of entacapone, a Parkinson’s disease drug.

Methods: We synthesised alkyne-tagged derivatives of entacapone and evaluated their suitability as molecular probes in ex vivo incubations with faecal communities or different Escherichia coli (E. coli) strains. Following incubation, tagged drugs were conjugated to a fluorescently labelled azide via click chemistry. Labelled cells were visualised, quantified, sorted via fluorescence-activated cell sorting (FACS), and identified via 16S ribosomal RNA (rRNA) gene amplicon sequencing.

Results: Entacapone alkyne derivatives retained the biological activity and effects of the original drug on the microbiota, significantly reducing microbial loads and shifting community composition across the three donors tested. Conjugation of alkyne-entacapone with a labelled azide revealed that between 80% to 96% of all microbial cells in a donor’s faecal sample accumulate entacapone. Nearly all taxa detected in incubations were recovered in labelled FACS fractions, confirming widespread uptake of the drug. Finally, we demonstrate that different E. coli strains exhibit varying levels of entacapone accumulation and identify a siderophore transporter that plays a role in this process.

Conclusion: Our findings reveal that entacapone is widely bioaccumulated by the gut microbiota across three donors and identify a key molecular mediator of this accumulation. This study expands the toolkit for investigating drug-microbiome interactions and holds significant potential to advance our understanding of drug-microbiome dynamics and therapeutic outcomes.

Keywords

Pharmaceuticals / bioorthogonal labelling / faecal microbiota / drug accumulation / siderophore transporter

References

[1] Maier L,Kuhn M.Extensive impact of non-antibiotic drugs on human gut bacteria.Nature2018;555:623-8 PMCID:PMC6108420

[2] Pereira FC,Kristensen JM.The Parkinson’s disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration.Nat Microbiol2024;9:3165-83 PMCID:PMC11602724

[3] Walsh J,Clarke G.Drug-gut microbiota interactions: implications for neuropharmacology.Br J Pharmacol2018;175:4415-29 PMCID:PMC6255959

[4] Weersma RK,Fu J.Interaction between drugs and the gut microbiome.Gut2020;69:1510-9 PMCID:PMC7398478

[5] la Cuesta-Zuluaga J, Boldt L, Maier L. Response, resistance, and recovery of gut bacteria to human-targeted drug exposure.Cell Host Microbe2024;32:786-93

[6] Mayneris-Perxachs J,Fernández-Real JM.The role of iron in host-microbiota crosstalk and its effects on systemic glucose metabolism.Nat Rev Endocrinol2022;18:683-98

[7] Yilmaz B.Gut Microbiota and Iron: The crucial actors in health and disease.Pharmaceuticals (Basel)2018;11:98 PMCID:PMC6315993

[8] Wu H,Tremaroli V.Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.Nat Med2017;23:850-8

[9] van Kessel SP,El-Gendy AO.Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease.Nat Commun2019;10:310 PMCID:PMC6338741

[10] Zimmermann M,Wegmann R.Mapping human microbiome drug metabolism by gut bacteria and their genes.Nature2019;570:462-7 PMCID:PMC6597290

[11] Klünemann M,Blasche S.Bioaccumulation of therapeutic drugs by human gut bacteria.Nature2021;597:533-8 PMCID:PMC7614428

[12] Garcia-Santamarina S,Devendran S.Emergence of community behaviors in the gut microbiota upon drug treatment.Cell2024;187:6346-6357.e20

[13] Wilson ID.Gut microbiome interactions with drug metabolism, efficacy, and toxicity.Transl Res2017;179:204-22 PMCID:PMC5718288

[14] Vergalli J,Pajovic J.The challenge of intracellular antibiotic accumulation, a function of fluoroquinolone influx versus bacterial efflux.Commun Biol2020;3:198 PMCID:PMC7189378

[15] Hatzenpichler R,Spietz RL.Next-generation physiology approaches to study microbiome function at single cell level.Nat Rev Microbiol2020;18:241-56 PMCID:PMC7133793

[16] Birch D,Staerk D,Nielsen HM.Fluorophore labeling of a cell-penetrating peptide induces differential effects on its cellular distribution and affects cell viability.Biochim Biophys Acta Biomembr2017;1859:2483-94

[17] Specht EA,Palmer AE.A critical and comparative review of fluorescent tools for live-cell imaging.Annu Rev Physiol2017;79:93-117 PMCID:PMC12034319

[18] Scinto SL,Hincapie R.Bioorthogonal chemistry.Nat Rev Methods Primers2021;1:30 PMCID:PMC8469592

[19] Bird RE,Yu X.Bioorthogonal chemistry and its applications.Bioconjug Chem2021;32:2457-79

[20] Valentini TD,Binder KA.Bioorthogonal non-canonical amino acid tagging reveals translationally active subpopulations of the cystic fibrosis lung microbiota.Nat Commun2020;11:2287 PMCID:PMC7210995

[21] Riva A,Cruz-Rubio JM.Identification of inulin-responsive bacteria in the gut microbiota via multi-modal activity-based sorting.Nat Commun2023;14:8210 PMCID:PMC10721620

[22] Nilsson I,Dovala D,Lapointe G.Molecular characterization and verification of azido-3,8-dideoxy-d-manno-oct-2-ulosonic acid incorporation into bacterial lipopolysaccharide.J Biol Chem2017;292:19840-8 PMCID:PMC5712623

[23] Deshpande PB,Dhameliya DR,Luthra PK. Alembic Ltd assignee Process for the preparation of entacapone. United States patent US 20100234632A1. 2010 Sep 16.

[24] Flanagan K,Lang M.Human-derived microRNA 21 regulates indole and L-tryptophan biosynthesis transcripts in the gut commensal Bacteroides thetaiotaomicron.mBio2025;16:e0392824 PMCID:PMC11898669

[25] Caporaso JG,Walters WA.Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample.Proc Natl Acad Sci U S A2011;108 Suppl 1:4516-22 PMCID:PMC3063599

[26] Martin M.Cutadapt removes adapter sequences from high-throughput sequencing reads.EMBnetjournal2011;17:10-2

[27] Callahan BJ,Rosen MJ,Johnson AJ.DADA2: High-resolution sample inference from Illumina amplicon data.Nat Methods2016;13:581-3 PMCID:PMC4927377

[28] Callahan BJ,Fukuyama JA,Holmes SP.Bioconductor workflow for microbiome data analysis: from raw reads to community analyses.F1000Res2016;5:1492 PMCID:PMC4955027

[29] Schloss PD,Ryabin T.Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.Appl Environ Microbiol2009;75:7537-41

[30] Oksanen J,Kindt R. vegan: Community Ecology Package [Internet]. Version 2.8-0. R package; 2025. Available from: https://CRAN.R-project.org/package=vegan (accessed 2025-10-24)

[31] McMurdie PJ.phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data.PLoS One2013;8:e61217 PMCID:PMC3632530

[32] Cole JR,Fish JA.Ribosomal Database Project: data and tools for high throughput rRNA analysis.Nucleic Acids Res2014;42:D633-42 PMCID:PMC3965039

[33] Love MI,Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol2014;15:550 PMCID:PMC4302049

[34] Hatzenpichler R,Tavormina PL,Tirrell DA.In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry.Environ Microbiol2014;16:2568-90 PMCID:PMC4122687

[35] Tornøe CW,Meldal M.Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides.J Org Chem2002;67:3057-64

[36] Yap BW.Comparisons of various types of normality tests.Journal of Statistical Computation and Simulation2011;81:2141-55

[37] Wang S,Patangia D.Assessment of absolute abundance in mother-infant gut microbiome using marine-sourced bacterial DNA spike-in and comparison with conventional quantification methods.Microbiome Res Rep2025;4:23 PMCID:PMC12367464

[38] Ding M,Yu R.Shared and non-shared sIgA-coated and -uncoated bacteria in intestine of mother-infant pairs.Int J Mol Sci2022;23:9873 PMCID:PMC9456154

[39] Fu SC,Hsieh YC,Lin SH.A pilot study exploring the association of entacapone, gut microbiota, and the subsequent side effects in patients With Parkinson’s Disease.Front Cell Infect Microbiol2022;12:837019 PMCID:PMC9022099

[40] Vandeputte D,D'hoe K.Quantitative microbiome profiling links gut community variation to microbial load.Nature2017;551:507-11

[41] Presolski SI,Finn MG.Copper-catalyzed azide-alkyne click chemistry for bioconjugation.Curr Protoc Chem Biol2011;3:153-62 PMCID:PMC3404492

[42] Baba T,Hasegawa M.Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection.Mol Syst Biol2006;2:2006.0008 PMCID:PMC1681482

[43] Raymond KN,Kim SS.Enterobactin: an archetype for microbial iron transport.Proc Natl Acad Sci2003;100:3584-8 PMCID:PMC152965

[44] Yi W,Liu X.Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry.Signal Transduct Target Ther2022;7:386 PMCID:PMC9716178

[45] Verhelst SHL,Willems LI.Bioorthogonal reactions in activity-based protein profiling.Molecules2020;25:5994 PMCID:PMC7765892

[46] Pinto M,Sardão VA.Cellular and mitochondrial toxicity of tolcapone, entacapone, and new nitrocatechol derivatives.ACS Pharmacol Transl Sci2024;7:1637-49 PMCID:PMC11091965

[47] Grün D,Kauffmann J.Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease.Parkinsonism Relat Disord2020;70:20-2

[48] Weis S,Unger MM.Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota.NPJ Parkinsons Dis2019;5:28 PMCID:PMC6884491

[49] Ruiz LM, Williams CL, Tamayo R. Enhancing bacterial survival through phenotypic heterogeneity.PLoS Pathog2020;16:e1008439 PMCID:PMC7241687

[50] Krismer J,Fontana S,Narwani A.Single-cell mass spectrometry reveals the importance of genetic diversity and plasticity for phenotypic variation in nitrogen-limited Chlamydomonas.ISME J2017;11:988-98 PMCID:PMC5364350

[51] Lindell AE,Patil KR.Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota.Nat Rev Microbiol2022;20:431-43 PMCID:PMC7615390

[52] Crudo F,Mihajlovic J.In vitro interactions of Alternaria mycotoxins, an emerging class of food contaminants, with the gut microbiota: a bidirectional relationship.Arch Toxicol2021;95:2533-49 PMCID:PMC8241668

[53] Forsberg MM,Savolainen J.The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.Eur J Pharm Sci2005;24:503-11

[54] D'Onofrio A,Stewart EJ.Siderophores from neighboring organisms promote the growth of uncultured bacteria.Chem Biol2010;17:254-64

[55] Kramer J,Kümmerli R.Bacterial siderophores in community and host interactions.Nat Rev Microbiol2020;18:152-63 PMCID:PMC7116523

[56] Cohen Z.Bioaccumulation as a mechanism of microbiome/drug interactions.Trends Microbiol2022;30:99-101

[57] Ngo JT,Deerinck TJ.Click-EM for imaging metabolically tagged nonprotein biomolecules.Nat Chem Biol2016;12:459-65 PMCID:PMC4871776

[58] Romano S,Bedarf JR,Hildebrand F.Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation.NPJ Parkinsons Dis2021;7:27 PMCID:PMC7946946

[59] Tannergren C,Lennernäs H.Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.Mol Pharm2009;6:60-73